Click here for Somavert® (pegvisomant) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
Somavert is used in the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-I concentrations or was not tolerated.
*As assessed by local ± central MRI analysis.
Professor Richard Ross, Consultant Endocrinologist, University of Sheffield, discusses the various treatments for acromegaly and how they each impact the pituitary tumour
To find out more about ACRODAT, supporting your patients or to order starter kits
Professor Partha Kar, Consultant in Diabetes and Endocrinology, Portsmouth Hospital NHS Trust, discusses the impact of acromegaly and its treatments on glycaemic control and diabetes
1. ACROSTUDY data on file. Final study report. November 2018.
2. Besser GM et al. Predictors and rates of treatment-resistant tumor growth in acromegaly. Eur J Endocrinol 2005;153:187–93.
3. Jiminez et al., Follow-up of pituitary tumour volume in patients with acromegaly treated with pegvisomant in clinical trials. European Journal of Endocrinology 2008: 159(5): 517–23.
4. Buchfelder M, et al. Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. Eur J Endocrinol, 2018;179(6):419–27.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020